GGHC
SLXP

Gilder Gagnon Howe & Co’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-14,507
Closed -$1.67M – 298
2014
Q4 		$1.67M Buy
14,507
+1,852
+15% +$224K 0.02% 190
2014
Q3 		$1.98M Buy
12,655
+82
+0.7% +$11.9K 0.03% 189
2014
Q2 		$1.55M Sell
12,573
-45,754
-78% -$5.06M 0.02% 215
2014
Q1 		$6.04M Buy
58,327
+47,902
+459% +$4.9M 0.08% 148
2013
Q4 		$938K Buy
+10,425
New +$831K 0.01% 209

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilder Gagnon Howe & Co's SLXP Position: Q1 2015 in Review

Gilder Gagnon Howe & Co sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 14,507 shares — an estimated $1.67M sold.

Gilder Gagnon Howe & Co first reported a position in SLXP in Q4 2013 and held it in 5 quarters. The position peaked at $6.04M in Q1 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

  • Gilder Gagnon Howe & Co reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 14,507 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $1.67M.
  • Gilder Gagnon Howe & Co first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 5 quarters.
  • Gilder Gagnon Howe & Co's SALIX PHARMACEUTICALS LTD DEL position peaked at $6.04M in Q1 2014.
  • 298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2015, filed 30 Apr 2015.